[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100522966":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":29,"centralContacts":33,"locations":41,"responsibleParty":104,"collaborators":106,"id":110,"slug":111,"hasResults":112,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":24,"eligibilityCriteria":116,"healthyVolunteers":112,"sex":117,"minAge":118,"maxAge":24,"enrollmentInfo":119,"targetDuration":24,"studyType":122,"phases":123,"briefSummary":125,"conditions":126,"keywords":128,"overallStatus":71,"whyStopped":24,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":139},{"fullName":5,"class":6},"Ottawa Heart Institute Research Corporation","OTHER",[8,13],{"label":9,"type":6,"description":10,"interventionNames":11},"Invasive Coronary Angiography","Patients in this arm will undergo annual CAV surveillance with ICA",[12],"Diagnostic Test: ICA",{"label":14,"type":6,"description":15,"interventionNames":16},"Positron Emission Tomography","Patients in this arm will undergo annual CAV surveillance with PET",[17],"Diagnostic Test: PET",[19,25],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DIAGNOSTIC_TEST","ICA","Patients will undergo annual CAV surveillance with ICA",[9],null,{"type":20,"name":26,"description":27,"armGroupLabels":28,"otherNames":24},"PET","Patients will undergo annual CAV surveillance with PET",[14],[30],{"name":31,"affiliation":5,"role":32},"Sharon Chih","PRINCIPAL_INVESTIGATOR",[34,38],{"name":31,"role":35,"phone":36,"phoneExt":24,"email":37},"CONTACT","613-696-7000","schih@ottawaheart.ca",{"name":39,"role":35,"phone":24,"phoneExt":24,"email":40},"Heather Ross","heather.ross@uhn.ca",[42,58,69,82,92],{"facility":43,"status":44,"city":45,"state":46,"zip":24,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"University of Calgary","NOT_YET_RECRUITING","Calgary","Alberta","Canada","CA",{"type":50,"coordinates":51},"Point",[52,53],-114.08529,51.05011,{"lat":53,"lon":52},[56],{"name":57,"role":35,"phone":24,"phoneExt":24,"email":24},"Robert Miller",{"facility":59,"status":44,"city":60,"state":46,"zip":24,"country":47,"countryCode":48,"cosmosGeoPoint":61,"geoPoint":65,"contacts":66},"Mazankowski Alberta Heart Institute","Edmonton",{"type":50,"coordinates":62},[63,64],-113.46871,53.55014,{"lat":64,"lon":63},[67],{"name":68,"role":35,"phone":24,"phoneExt":24,"email":24},"Daniel Kim",{"facility":70,"status":71,"city":72,"state":73,"zip":74,"country":47,"countryCode":48,"cosmosGeoPoint":75,"geoPoint":79,"contacts":80},"University of Ottawa Heart Institute","RECRUITING","Ottawa","Ontario","K1Y 4W7",{"type":50,"coordinates":76},[77,78],-75.69812,45.41117,{"lat":78,"lon":77},[81],{"name":31,"role":35,"phone":24,"phoneExt":24,"email":24},{"facility":83,"status":44,"city":84,"state":73,"zip":24,"country":47,"countryCode":48,"cosmosGeoPoint":85,"geoPoint":89,"contacts":90},"Toronto-General Hospital - University Health Network","Toronto",{"type":50,"coordinates":86},[87,88],-79.39864,43.70643,{"lat":88,"lon":87},[91],{"name":39,"role":35,"phone":24,"phoneExt":24,"email":24},{"facility":93,"status":44,"city":94,"state":95,"zip":24,"country":47,"countryCode":48,"cosmosGeoPoint":96,"geoPoint":100,"contacts":101},"Montreal Heart Institute","Montreal","Quebec",{"type":50,"coordinates":97},[98,99],-73.58781,45.50884,{"lat":99,"lon":98},[102],{"name":103,"role":35,"phone":24,"phoneExt":24,"email":24},"Tremblay-Gravel",{"type":105,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR",[107],{"name":108,"class":109},"Canadian Institutes of Health Research (CIHR)","OTHER_GOV","100522966","mariner-trial-multiparametric-cardiac-pet-for-cav-surveillance-after-heart-transplantation-100522966",false,"NCT06089486","MARINER Trial: Multiparametric Cardiac PET for CAV Surveillance After Heart Transplantation","Multiparametric Cardiac Positron Emission Tomography for Cardiac Allograft Vasculopathy Surveillance After Heart Transplantation","Inclusion Criteria:\n\n1. Post heart transplant 2-10 years.\n2. Age ≥18 years.\n3. Able to provide informed consent.\n\nExclusion Criteria:\n\n1. Contraindication to dipyridamole due to severe aortic stenosis.\n2. Contraindication to dipyridamole due to 2:1 or greater AV block without pacemaker.\n3. Contraindication to dipyridamole due to severe bronchospasm.\n4. Unable to undergo coronary angiography due to allergy to iodinated contrast.\n5. Unable to undergo coronary angiography due to glomerular filtration rate ≤30 mL\u002Fmin\u002F1.73 m2. for non-dialysis patients as determined by local laboratory analysis.\n6. Unable to undergo coronary angiography due to unsuitable vascular access.\n7. Treated rejection ≤1-month.\n8. Unstable angina or MI ≤7 days.","ALL","18 Years",{"count":120,"type":121},576,"ESTIMATED","INTERVENTIONAL",[124],"NA","Cardiac allograft vasculopathy (CAV) is a common complication affecting heart transplant patients. This condition causes narrowing of the heart arteries leading to graft dysfunction. Surveillance for CAV is vital; however an ideal approach has not been established. The goal of this study is to assess whether noninvasive positron emission tomography (PET) based surveillance is non-inferior to invasive coronary angiography (ICA) surveillance.",[127],"Cardiac Allograft Vasculopathy",[129],"Heart Transplant","2026-04-29",{"date":132,"type":133},"2026-05-06","ACTUAL",{"date":135,"type":133},"2024-01-08",{"date":137,"type":121},"2029-03",{"name":5,"class":6},5]